ArticleBriefings in bioinformatics2026
MMP3C v2: a network-based framework decoding metabolic plasticity in rheumatoid arthritis, enabling accurate diagnosis and uncovering cell-type-specific metabolic rewiring.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Metabolic plasticity, the ability of cells to dynamically adapt their metabolic pathways in response to changing environments, is a hallmark of rheumatoid arthritis (RA) pathogenesis and plays a critical role in immune dysfunction. However, scalable methods to quantify inter-pathway crosstalk in RA remain lacking. To address this gap, we present MMP3C v2, an updated network-based framework that integrates gene expression with protein-protein interaction network topology to compute directed pairwise metabolic plasticity (PMP) scores. We applied MMP3C v2 to ~3400 bulk transcriptomes (RA, osteoarthritis, systemic lupus erythematosus, and healthy controls) and ~228 000 single-cell transcriptomics from blood and synovium to profile RA-associated PMP alterations and develop diagnostic classifiers. We found that a single PMP-derived signature demonstrated strong predictive capability for diagnosis. Then, we developed a feature selection pipeline and combined it with 110 machine learning model combinations, by which we established the optimal ensemble classifier (stepwise forward selection + ridge regression), achieving robust and generalized performance (mean area under the curve (AUC) = 0.935; mean F1 score = 0.915) across 12 independent validation cohorts, outperforming seven previously published models. Single-cell analysis revealed cell-type-specific PMP remodeling: a Warburg-like shift in synovial macrophages (↑glycolysis, ↑pentose phosphate pathway, ↓oxidative phosphorylation). Cell-cell communication analysis highlighted FN1-centered signaling linked to glucose metabolic remodeling in myofibroblasts. Collectively, MMP3C v2 establishes metabolic pathway crosstalk as a core diagnostic feature of RA, enabling interpretable and cross-platform diagnostic modeling and the identification of cell-type-specific PMP patterns. The open-source R package mmp3c supports reproducible analysis and broad application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.